Adrinor 1mg 1 ml Injection
IndicationsAdjunctive use in the management of cardiac arrest. It is used in cardiopulmonary resuscitation. Intracardiac puncture and intramyocardial injection of adrenaline may be effective when external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail. Adrenaline is a drug that leads to increased blood pressure, increased heart rate, increased air entry, increased blood glucose, stimulates cardiac activity and reduces allergic reactions by reducing inflammatory response caused by histamine. Due to these properties, it is used for the treatment of allergic and anaphylactic reactions. Adrenaline is the favored treatment for anaphylactic shock and should be administered immediately if a person begins exhibiting severe allergic reactions. Adrenaline is also used in life threatening asthma when failing ventilation and continued deterioration despite nebulizer therapy.DescriptionsAdrenaline is a direct-acting sympathomimetic agent exerting its effect on alpha and beta-adrenoceptors. The overall effect of adrenaline depends on the dose, and may be complicated by the homeostatic reflex responses. In resuscitation procedures it is used to increase the efficacy of basic life support. It is a positive cardiac inotrope. Major effects are increased systolic blood pressure by arterioral and venous vasoconstriction (alpha1 effects), reduced diastolic pressure, tachycardia and hyperglycaemia. Adrenaline is rapid in onset and with short duration. After IV infusion the half-life is approximately 5-10 minutes. It is rapidly distributed to the heart, spleen, several glandular tissues and adrenergic nerves. Adrenaline is rapidly metabolised in the liver and tissues by oxidative de-amination and O-methylation followed by reduction or by conjugation with glucuronic acid or sulphate. Up to 90% of the IV dose is excreted in the urine as metabolites. It is approximately 50% bound to plasma proteins.Dosage & AdministrationCardiac arrest: 1. Intravenous injection: 1 mg injection repeated every 2-3 minutes as necessary. 2. Endotracheal: 2-3 mg via an endotracheal tube, repeated as necessary. 3. Intracardiac injection: 0.1 to 1 mg, direct into the atrium of the heart. 4. Intraspinal use: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption). Anaphylaxis, asthma or severe bronchospasm: Adult dose is 0.25 - 0.5 mg. It may be repeated at 5 minutes intervals until perfusion and respiratory status normalizes. In case of dose dilution: 1 mg of Adrenaline to be diluted in 9 ml Normal Saline. Children: Intravenous injection: Initially 10 mcg/kg body weight, not to exceed 250 mcg. May be repeated every 3-5 minutes if necessary. Subsequent doses should be 100 mcg/kg.Side EffectsAnxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics.PrecautionsThe solution should not be used if it is pinkish or darker than slightly yellow or if it contains a precipitate. Adrenaline is readily destroyed by alkalies and oxidizing agents. In the latter category are Oxygen, Chlorine, Iodine, Permanganates, Chromates, Nitrites and salts of easily reducible metals, especially Iron. Adrenaline should not be mixed with Sodium bicarbonate; the solution is oxidised to adrenochrome and then forms polymers. Special warnings and precautions for use Administer slowly with caution to elderly patients and to patients with ischemic heart disease, hypertension, diabetes mellitus, hyperthyroidism or psychoneurosis. Use with extreme caution in patients with long-standing bronchial asthma and emphysema who have developed degenerative heart disease. Anginal pain may be induced when coronary insufficiency is present.ContraindicationsHypertension, arteriosclerosis, coronary disease and hyperthyroidism. Not to be given to patients taking monoamine oxidase inhibitors.Use in Pregnancy & LactationPregnancy Category C. It crosses the placenta and is excreted in breast milk. Adrenaline should only be used in pregnancy if the potential benefits outweigh the risks to the fetus. Lactating mothers: It is excreted in breast milk and therefore Adrenaline is not recommended for use during lactation because of the risk of adverse effects of infants.Drug InteractionUse of Adrenaline with excessive doses of digitalis, mercurial diuretics or other drugs that sensitize the heart to arrhythmias is not recommended. The adverse effects of Adrenaline may be potentiated by tricyclic antidepressants; certain antihistamines; e.g, Diphenhydramine, Tripelennamine, Chlorpheniramine and L-thyroxine Sodium.OverdoseSymptoms: Cardiac arrhythmia leading to ventricular fibrillation, severe hypertension leading to pulmonary edema and cerebral hemorrhage. Treatmen..
Tk.25.00/=
Ascon 100 mcg/puff Inhalation Aer
Ascon 100 mcg/puff Inhalation AerDESCRIPTIONBeclometasone Dipropionate (Ascon) is a synthetic halogenated corticosteroid with anti-inflammatory activity. BeclometasoneDipropionate (Ascon) given by inhalation has a potent glucocorticoid anti-inflammatory action within the lungs without the side effects observed when steroids are administered systemically. When used as an Inhaler, the medication goes directly into the lungs and very little finds its way into the rest of the body.COMPOSITIONEach actuation delivers Beclometasone Dipropionate BP 250 mcg .INDICATIONSAscon is indicated for the management of patients with bronchial asthma including :• Patients whose asthma is inadequately controlled by bronchodilator therapy alone and asthma is becoming worse.• Patients whose asthma is not controlled by the combined use of bronchodilator and sodium cromoglycate.• Patients with severe asthma being treated with systemic corticosteroid or synthetic or actual adrenocorticotropic derived hormone (ACTH).DOSAGE AND ADMINISTRATIONMaximum therapeutic benefit may be achieved in 1-3 months from any of corticosteroid inhalation therapy. Patients should be given a starting dose of inhaled Beclometasone Dipropionate that is appropriate for the severity of their disease. The dose may then be adjusted until asthma is controlled or reduced to the minimum effective dose according to individual response. AdultsThe usual recommended dose is 200 mcg (2 Inhalations) twice daily. In more severe cases dosage may be started at or increased to 600 to 800 mcg per day, and subsequently reduced when the patient's asthma has established. The total daily dose may be administered as two, three or four divided doses. Children The usual starting dose is 100 mcg (1 Inhalation) twice daily. Sometimes patients may require 100 mcg or 200 mcg (1 or 2 Inhalations) twice daily.OR AS DIRECTED BY THE PHYSICIAN.CONTRAINDICATIONSBeclometasone is contraindicated to the patients hypersensitive to it or any of its components. Special care is necessary in patients with active or quiescent pulmonary tuberculosis.PRECAUTIONSPatients should be instructed on the proper use of the Inhalers to ensure that the drug reaches the target areas within the lungs. The maximum daily administration of Beclometasone Inhaler should not exceed 1 mg. Significant reduction in plasma cortisone levels has been reported in patients who receive twice this amount.They should also be made aware that Beclometasone Inhaler has to be used regularly for optimum benefit. Patients should be made aware of the prophylactic nature of therapy with Beclometasone Inhaler and it should be taken regularly, even when they are asymptomatic.Treatment with Ascon Inhaler should not be stopped abruptly.SIDE EFFECTSCandidiasis of the mouth and throat may occur in some patients,the incidence of which is increased with doses greater than 400 mcg Beclometasone Dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Symptomatic Candidiasis can be treated with topical antifungal therapy whilst still continuing with the Beclometasone Inhaler. In some patients, inhaledBeclometasone Dipropionate may cause hoarseness or throat irritation. It may be helpful to rinse mouth with water immediately after inhalation. As with other inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted.Use in pregnancyThe use of Beclometasone Dipropionate in pregnancy requires that the possible benefits of the drug be weighed against the possible hazards. It should be noted that the drug has been in widespread use for many years without apparent ill consequence.Use in lactationNo specific studies examining the transference of BeclometasoneDipropionate into the milk of lactating animals have been performed. It is reasonable to assume that Beclo-metasoneDipropionate is secreted in milk but at the dosages used for direct inhalation there is low potential for significant levels in breast milk.The use of Beclometasone Dipropionate in mothers breast feeding their babies requires that the therapeutic benefits of the drug be weighed against the potential hazards to the mother and baby.SUPPLYEach canister contains 200 metered doses, each containing 250 mcg of Beclometasone Dipropionate BP...
Tk.270.81/=
Ascon 250 Inhaler
Ascon 250 InhalerDESCRIPTIONBeclometasone Dipropionate (Ascon) is a synthetic halogenated corticosteroid with anti-inflammatory activity. BeclometasoneDipropionate (Ascon) given by inhalation has a potent glucocorticoid anti-inflammatory action within the lungs without the side effects observed when steroids are administered systemically. When used as an Inhaler, the medication goes directly into the lungs and very little finds its way into the rest of the body.COMPOSITIONEach actuation delivers Beclometasone Dipropionate BP 250 mcg .INDICATIONSAscon is indicated for the management of patients with bronchial asthma including :• Patients whose asthma is inadequately controlled by bronchodilator therapy alone and asthma is becoming worse.• Patients whose asthma is not controlled by the combined use of bronchodilator and sodium cromoglycate.• Patients with severe asthma being treated with systemic corticosteroid or synthetic or actual adrenocorticotropic derived hormone (ACTH).DOSAGE AND ADMINISTRATIONMaximum therapeutic benefit may be achieved in 1-3 months from any of corticosteroid inhalation therapy. Patients should be given a starting dose of inhaled Beclometasone Dipropionate that is appropriate for the severity of their disease. The dose may then be adjusted until asthma is controlled or reduced to the minimum effective dose according to individual response. AdultsThe usual recommended dose is 200 mcg (2 Inhalations) twice daily. In more severe cases dosage may be started at or increased to 600 to 800 mcg per day, and subsequently reduced when the patient's asthma has established. The total daily dose may be administered as two, three or four divided doses. Children The usual starting dose is 100 mcg (1 Inhalation) twice daily. Sometimes patients may require 100 mcg or 200 mcg (1 or 2 Inhalations) twice daily.OR AS DIRECTED BY THE PHYSICIAN.CONTRAINDICATIONSBeclometasone is contraindicated to the patients hypersensitive to it or any of its components. Special care is necessary in patients with active or quiescent pulmonary tuberculosis.PRECAUTIONSPatients should be instructed on the proper use of the Inhalers to ensure that the drug reaches the target areas within the lungs. The maximum daily administration of Beclometasone Inhaler should not exceed 1 mg. Significant reduction in plasma cortisone levels has been reported in patients who receive twice this amount.They should also be made aware that Beclometasone Inhaler has to be used regularly for optimum benefit. Patients should be made aware of the prophylactic nature of therapy with Beclometasone Inhaler and it should be taken regularly, even when they are asymptomatic.Treatment with Ascon Inhaler should not be stopped abruptly.SIDE EFFECTSCandidiasis of the mouth and throat may occur in some patients,the incidence of which is increased with doses greater than 400 mcg Beclometasone Dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Symptomatic Candidiasis can be treated with topical antifungal therapy whilst still continuing with the Beclometasone Inhaler. In some patients, inhaledBeclometasone Dipropionate may cause hoarseness or throat irritation. It may be helpful to rinse mouth with water immediately after inhalation. As with other inhalation therapy, the potential for paradoxical bronchospasm should be kept in mind. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted.Use in pregnancyThe use of Beclometasone Dipropionate in pregnancy requires that the possible benefits of the drug be weighed against the possible hazards. It should be noted that the drug has been in widespread use for many years without apparent ill consequence.Use in lactationNo specific studies examining the transference of BeclometasoneDipropionate into the milk of lactating animals have been performed. It is reasonable to assume that Beclo-metasoneDipropionate is secreted in milk but at the dosages used for direct inhalation there is low potential for significant levels in breast milk.The use of Beclometasone Dipropionate in mothers breast feeding their babies requires that the therapeutic benefits of the drug be weighed against the potential hazards to the mother and baby.SUPPLYEach canister contains 200 metered doses, each containing 250 mcg of Beclometasone Dipropionate BP...
Tk.320.96/=
Axinat 120 Metered Inhaler
Axinat 120 Metered InhalerndicationsInhaled Salmeterol exerts a significant bronchodilating effect within 10 to 20 minutes of single-dose administration with asthma and this effect lasts for up to 12 hours or more.Salmeterol has a beneficial effect on airway mucociliary clearance that will reduce the incidence of respiratory tract infections.Salmeterol produces a significant protective effect against Exercise Induced Asthma (EIA) for up to 9 to 12 hours in both adolescents and adults.Salmeterol improves the overnight PEFR (Peak Expiratory Flow Rate) and controls the symptoms of the patients with nocturnal asthma. The use of Salmeterol avoids exposure of children to theophylline or high-dose corticosteroid, with their attendants risks.Addition of Salmeterol to inhaled corticosteroid therapy is significantly more effective in terms of an improvement in lung function, symptom control and a reduction in the use of rescue bronchodilator therapy (use of short acting beta2-agonist).Addition of Salmeterol to inhaled corticosteroid therapy also significantly reduces the use of inhaled corticosteroidsPharmacologySalmeterol stimulates intracellular adenyl cyclase, the enzyme that catalyses the conversion of ATP to cyclic-3′,5′-adenosine monophosphate (cAMP) resulting in relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from mast cells.ContraindicationsMonotherapy in the treatment of asthma. Treatment of status asthmaticus, other acute episodes of asthma or COPD.Side EffectsDose related tremor, subjective palpitations and headaches are usually mild and transient. Skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported.Overdose EffectsSymptoms: Dizziness, HTN or hypotension, tremor, headache, tachycardia, hypokalaemia, seizures, angina, arrhythmias, nervousness, muscle cramps, dry mouth, palpitations, nausea, fatigue, malaise, insomnia, hyperglycaemia, metabolic acidosis.Management: Symptomatic and supportive treatment. β-blockers may be considered but should be used with caution...
Tk.125.00/=
Beclomet-Nasal Spray
Beclomet-NSIndicationsProphylaxis and treatment of seasonal & perennial allergic rhinitis including hay fever & non-allergic (vasomotor) rhinitis. Prevention of recurrence of nasal polyps following surgical removal.PharmacologyFollowing topical administration into the nasal mucosa, Beclomethasone Dipropionate produces anti-inflammatory and vasoconstrictor effects. The exact mechanism of these actions remain unknown, but may involve reductions in the following: number of mediator cells (basophil, leukocytes and mast cells) at the epithelial level, number of eosinophils, sensitivity of sensory nerves to mechanical stimuli, secretory response to cholinergic receptor stimulation, and fibroblast activity. Other mechanisms may involve inhibition of capillary dilation and permeability, stabilization of lysosomal membranes and subsequent prevention of release of proteolytic enzymes.ContraindicationsContraindicated in patients with a history of hypersensitivity to any of its components. Infections of the nasal passages and paranasal sinuses should be appropriately treated but do not constitute a specific contraindication to treatment with Beclomethasone nasal spray.Side EffectsRare instances of nasal septum perforation have been reported following intranasal administration. As with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste & smell and epistaxis have been reported rarely. Rare instances of wheezing, cataracts, glaucoma and increased intra-ocular pressure have been reported following the intranasal use of Beclomethasone.Overdose EffectsInhalation of excessive doses over a short time period may suppress hypothalamic pituitary adrenal (HPA) function, and no special emergency action need to be taken, rather treatment should be continued at recommended dose. HPA function recovers within one or two day..
Tk.120.37/=
-140x140.jpg "Beclomin 250 HFA")
Beclomin 250 HFA
Indication: Beclometasone 100 & 250 HFA Inhaler is indicated in the prophylactic management of mild, moderate, or severe asthma in adults or children. Beclometasone dipropionate given by inhalation offers preventative treatment for asthma. It provides effective anti-inflammatory action in the lungs with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. Mild asthma : Patients requiring symptomatic bronchodilator asthma medication on a regular basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma : Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. Many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly, or eliminate, their requirement for oral corticosteroids when they are transferred to high dose inhaled beclometasone dipropionate...
Tk.320.96/=
Becospary Nasal Spray
Becospary N-SprayIndication:Seasonal & perennial allergic rhinitis including hay fever & non-allergic (vasomotor) rhinitis.Dosage & Administration:Adults : 02 sprays in each nostril twice daily.Children (6 to 12 years of age): 01 spray in each nostril twice daily.Children under 6 years of age: Not recommended.Preparation:Becospray® : Each bottle contains Beclomethasone dipropionate aqueous suspension adequate for 200 metered doses...
Tk.146.01/=
Cinarex-D Ophthalmic suspension
...to fight infections and inflammations togetherDexamethasone is glucocorticoid. It has an anti-inflammatory and anti-allergic action. It is used topically in the treatment of inflammatory conditions of the anterior segment of the eye. The efficacy of corticosteroids for the treatment of inflammatory conditions of the eye is well established. It works by reducing swelling. Tobramycin is an aminoglycoside antibiotic for topical administration to the eyes. It works by stopping the growth of bacteria by inhibiting protein synthesis. Tobramycin provide antibacterial protection against susceptible becteria.This combination eye drop is indicated for reduction of inflammation and prophylaxis of infection following cataract surgery.Cinarex®-D Ophthalmic suspension: Plastic dropper bottle contains 5 ml sterile suspension. Each ml contains Dexamethasone USP 1 mg and Tobramycin USP 3 mg.Ensures effective relief from inflammation after ocular surgeryEnsures comfort to the patientsSafe and well toleratedMost suitable for blepharo-keratoconjunctivitis..
Tk.150.00/=
Decomit 100 HFA inh
Decomit® HFA is a metered dose inhaler (MDI) contains beclomethasone dipropionate. It is environment friendly inhaler which contains ozone-benign propellant replacing CFC propellant. Decomit HFA is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Beclomethasone dipropionate is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone dipropionate may reduce or eliminate the need for the systemic corticosteroids.Decomit HFA is an advanced HFA formulation of beclomethasone dipropionate solution with an average particle size of 1.1 micron. The small extrafine particles achieved in Decomit HFA results in greater drug deposition in the lungs, including the large, intermediate, and small airways, and less deposition in the oropharynx.Because of local actions, greater drug deposition in the lungs is not associated with greater systemic side effects.Decomit HFA because of having small particle size, effectively treats inflammation in the large, intermediate and small airways of the lungs.Decomit HFA also ensures minimal drug deposition in the mouth and throat.Moreover, because of efficient delivery Decomit HFA improved asthma control at less than half the dose of CFC-BDPBeing solution, Decomit HFARemains stable in hot & humid climateDoes not require shaking before use..
Tk.270.00/=
Decomit 50 HFA inh
Decomit 50 HFA inhDecomit® HFA is a metered dose inhaler (MDI) contains beclomethasone dipropionate. It is environment friendly inhaler which contains ozone-benign propellant replacing CFC propellant. Decomit HFA is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Beclomethasone dipropionate is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone dipropionate may reduce or eliminate the need for the systemic corticosteroids.Decomit HFA is an advanced HFA formulation of beclomethasone dipropionate solution with an average particle size of 1.1 micron. The small extrafine particles achieved in Decomit HFA results in greater drug deposition in the lungs, including the large, intermediate, and small airways, and less deposition in the oropharynx.Because of local actions, greater drug deposition in the lungs is not associated with greater systemic side effects.Decomit HFA because of having small particle size, effectively treats inflammation in the large, intermediate and small airways of the lungs.Decomit HFA also ensures minimal drug deposition in the mouth and throat.Moreover, because of efficient delivery Decomit HFA improved asthma control at less than half the dose of CFC-BDPBeing solution, Decomit HFARemains stable in hot & humid climateDoes not require shaking before use..
Tk.220.00/=
Decomit N. Spray
DecomitDecomit® HFA is a metered dose inhaler (MDI) contains beclomethasone dipropionate. It is environment friendly inhaler which contains ozone-benign propellant replacing CFC propellant. Decomit HFA is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Beclomethasone dipropionate is also indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone dipropionate may reduce or eliminate the need for the systemic corticosteroids.Decomit HFA is an advanced HFA formulation of beclomethasone dipropionate solution with an average particle size of 1.1 micron. The small extrafine particles achieved in Decomit HFA results in greater drug deposition in the lungs, including the large, intermediate, and small airways, and less deposition in the oropharynx.Because of local actions, greater drug deposition in the lungs is not associated with greater systemic side effects.Decomit HFA because of having small particle size, effectively treats inflammation in the large, intermediate and small airways of the lungs.Decomit HFA also ensures minimal drug deposition in the mouth and throat.Moreover, because of efficient delivery Decomit HFA improved asthma control at less than half the dose of CFC-BDPBeing solution, Decomit HFARemains stable in hot & humid climateDoes not require shaking before use..
Tk.146.00/=
Dexonex 0.05 mg TAB
Indication: Various types of dermatological disorders & allergic Disorders; Severe Respiratory Disorders like - severe Bronchial Asthma, non-specific chronic Obstructive lung disease; Primary / secondary Adrenocortical insufficiency; Ocular inflammatory conditions which are unresponsive to topical corticosteroids; Adjunctive therapy for various rheumatic disorders; other indications where glucocorticoid therapy is required.Dosage & Administration:-Preparation: - ..
Tk.0.89/=
Dexonex 5 mg/ml Inj
Indication: Various types of dermatological disorders & allergic Disorders; Severe Respiratory Disorders like - severe Bronchial Asthma, non-specific chronic Obstructive lung disease; Primary / secondary Adrenocortical insufficiency; Ocular inflammatory conditions which are unresponsive to topical corticosteroids; Adjunctive therapy for various rheumatic disorders; other indications where glucocorticoid therapy is required.Dosage & Administration:-Preparation: - ..
Tk.20.06/=
Dexonex-C Eye/Ear Drops 5 ml
Indication: Eye: For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. It is also indicated in chronic anterior uveitis and corneal injury from chemical radiation or thermal burns or penetration of foreign bodies. The combination can also be used for post-operative in ammation and any other ocular in ammation associated with infection. Ear: Otitis externa, Otitis media and chronic suppurative otitis media.Dosage & Administration:Eye Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcer is two drops into the a ected eye every 15 minutes for the rst six hours and then two drops into the a ected eye every 30 minutes for the remainder of the rst day. On the second day, instill two drops in the a ected eye hourly. On the third through the fourteenth day, place two drops in the a ected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred. Bacterial Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next ve days. Ear: For all infections two to three drops every two to three hours initially. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely...
Tk.70.21/=
Dextrobac Eye Drops
Dextrobac Eye DropsDescriptionDextrobac eye drop is a combination preparation of dexamethasone and tobramycin. Dexamethasone is a corticosteroid and tobramycin is an aminoglycoside antibiotic . It is used in the eye to prevent permanent damage,which may occur with certain eye problemsIndicationsDextrobac eye drops are used to treat inflammation and a possible infection that may result from the surgery of the eyeDosage & AdministrationAdults: One drop instilled into the conjunctival sac every 4 to 6 hours while the patient is awake. During the initial 24 to 48 hours, the dosage may be increased to one drop every two hours while the patient is awake, for a maximum of 24 days. Frequency should be decreased gradually as the improvement in clinical signs.Children: Safety and effectiveness in children below the age of 2 years have not been established.Side EffectsTobramycin may cause hypersensitivity and localised ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than 4% of patients. The reactions due to dexdamethasone are: elevation of intraocular pressure (IOP), with possible development of glaucoma and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.PrecautionsShake the bottle well before use. To prevent contamination do not touch the tip of the bottle to affected eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.Use in Pregnancy & LactationSafety for use during pregnancy and lactation in humans has not been establishedOver DoseA topical overdose of Dextrobac eye drops may be flushed from the eye(s) with lukewarm tap water.Storage- Store the bottle below 25 °C.- Do not refrigerate or freeze.- Keep out of reach of children.- Do not use more than 4 weeks after opening the bottleCommercial PackDextrobac Sterile Ophthalmic Suspension : Plastic dropper bottle containing 5 ml eye drops...
Tk.150.00/=
Inflavis Eye & Ear Drops
1. What Inflavis is and what it is used for (Mainly description as short form)? Inflavis eye drop contains Dexamethasone Phosphate 2. Before you take Inflavis? Do not take this medicine and tell your doctor if: Herpes simplex and other viral diseases of the cornea and conjunctiva, fungal disease, ocular tuberculosis, untreated purulent infections and hypersensitivity to any component of the preparation. Patients with soft contact lenses should not use this preparation.Take special care with Inflavis Check with your doctor before taking this medicine if: Topical corticosteroids should never be given for an undiagnosed red eye as inappropriate use is potentially blinding. Because of the risk of “steroid glaucoma” and cataract formation the intraocular pressure and the lens must be checked frequently during use of this preparation. To avoid the risk of enhancement of herpetic corneal disease, frequent slit-lamp examination is essential. Topical steroids may mask or enhance the activity of acute purulent eye infections. In such cases antibiotic therapy is mandatory. Persistent corneal ulceration following long-term topical steroid use may be due to fungal invasion. Taking other medicines None relevant to topical use. Pregnancy and breast-feeding There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human pregnancy. 3. How to take Inflavis(Administration)? Taking this medicine (Do not need to change) Always use Inflavis exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. How much to take? Eye: The frequency of instillation of drops and the duration of treatment will vary depending upon the severity of the underlying condition and the response to treatment. Severe inflammations require one to two drops instilled into the eye every thirty to sixty minutes until a satisfactory response occurs. If you take more Inflavis than you should If you have too much of this medicine, talk to your doctor straight away. If you forget to take Inflavis If you forget to take a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose If you stop taking Inflavis Do not stop taking this medicine without talking to your doctor. You should not stop taking Inflavis just because you feel better. This is because the problem may come back or get worse again. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, Inflavis can cause side effects, although not everybody gets them. Topical steroid use may result in increased intraocular pressure leading to optic nerve damage, reduced visual acuity and visual field defects. Tell your doctor if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet 5. How to store? Store in a cool and dry place, away from light. Keep out of reach of children Inflavis Eye & Ear Drops Prescribing InformationLocated in: Eye Care..
Tk.70.00/=
